1·Laboratory: increase Prothrombin time (PT).
实验室检查：凝血酶原时间(PT)延长。
2·Used for biochemical studies, to prevent the prothrombin into thrombin.
用于生化研究，防止凝血酶原转变成凝血酶。
3·Prothrombin G20210A mutation can lead to plasma prothrombin level increase.
凝血酶原基因g20210a突变，可导致血浆凝血酶原水平升高。
4·Objective: to investigate the part influence factors of prothrombin time assay.
目的：探讨凝血酶原时间测定的部分影响因素。
5·When the tissue damage, the release of thromboplastin to prothrombin into thrombin.
当组织损伤时，释放出凝血致活酶，把凝血酶原变成凝血酶。
6·Objective to explore effects of blood platelets and prothrombin time on mifepristone.
目的探讨米非司酮对血小板、血浆凝血酶原时间的影响。
7·Results No prothrombin gene G20210A mutation was found in both patients and controls.
结果所有受检者均未发现凝血酶原G20210A基因突变。
8·In contrast, there wag no abnormal prothrombin in the rat plasma during its liver regeneration.
诱癌早期的大鼠血浆即出现了高水平异常凝血酶原，它可用于肝癌的早期诊断。
9·Conclusion Prothrombin 20210a gene mutation may increase genetic susceptibility of gastric cancer.
结论凝血酶原突变基因20210 A可能增加了胃癌的遗传易感性。
10·Patients with hypoproteinemia or prolonged prothrombin time (PT) were often accompanied by hypocalcemia.
低蛋白血症和PT延长的病例伴有低血钙较常见。
1·The majority of patients with ascites due to cirrhosis have prolongation of the prothrombin time and some degree of thrombocytopenia.
大多数肝硬化腹水的患者凝血酶原时间延长并有一定程度的血小板减少。
2·Objective: to investigate the part influence factors of prothrombin time assay.
目的：探讨凝血酶原时间测定的部分影响因素。
3·Objectives: Using normal plasmas and criterion plasmas to establish a kind of accurate and feasible method that could measure international normalized ratio (INR) of prothrombin time (PT).
目的：利用正常血浆和定标血浆，建立一种准确可靠、易于实验室开展的凝血酶原时间国际标准化比值检测方法。
4·Technical conditions for adsorption and separation of prothrombin complex concentrates from human plasma with CG-6 macroporous anion-exchange resin were optimized.
优化了CG - 6型大孔阴离子交换树脂从人血浆中吸附和分离凝血酶原复合物的工艺条件。
5·Objective To investigate the relationship between serum cholinesterase (CHE), prothrombin activity (PTA) and the clinical type, disease condition and prognosis in the viral hepatitis patients.
目的研究血清胆碱酯酶(CHE)、凝血酶原活动度(PTA)与病毒性肝炎临床分型、病情及预后之间的关系。